Program at a Glance

  • Program at a Glance
  • April 1, 2021
  • April 2, 2021
  • April 3, 2021
Date Thursday, April 1 Friday, April 2 Saturday, April 3
Room R1 R2 R3 R1 R2 R3 R4 R1 R2 R3
07:30-08:00 Business Meeting
(07:30-08:30)
08:00-08:30 Registration Registration Registration
08:30-09:00 Opening Remark (08:50-09:00) Working party Report
(08:30-09:00)
09:00-10:30 [SS01]
Acute Lymphoblastic Leukemia
[SS02]
B-Cell Lymphoma
[ES01]
Myelodysplastic Syndrome
[JS04]
ASH-KSH Joint Symposium
[SS06]
Thrombotic issues in hematology
[ES03]
Lymphoma
[SS10]
Immunotherapy/
Transplantation
[SS11]
Pediatric Disease
[SS12]
T-Cell Lymphoma /HD
10:30-11:15 [PL01]
Cutting Edge of Emerging Therapies
[PL02]
Clinical Hematology Lecture
[PL03]
Genomics in Hematologic Malignancies
11:15-11:30 Break Break Break
11:30-12:10 [SY01]
Astellas
[SY02]
Sanofi-Aventis
[SY03]
BMS-Celgene
[SY04]
Handok
[SY05]
Roche
[SY06]
Amgen
[SY07]
Janssen
[SY08]
Novartis
[SY09]
Kyowa Kirin
[SY10]
Takeda
12:10-12:55 E-poster Exhibition (12:10-12:55) E-poster Exhibition (12:10-12:40) Award Ceremony & Closing (12:10-12:55)
12:55-14:25 [AS01]
Asian Session 1
(12:55-13:55)
[JS01]
KAI-KSH Joint Session
(12:55-14:25)
[SS0 3]
Advances in Technology
(12:55-14:25)
[OP01]
Acute Leukemia
(12:40-13:40)
[OP02]
Laboratory Hematology
(12:40-13:40)
[OP03]
Lymphoma and MM
(12:40-13:40)
[OP04]
Benign Hematology
(Anemia, Thrombocytopenia)
(12:40-13:40)
14:25-14:40 Break (14:25-14:40) Break (13:40-13:55)
Presidential Symposium
(13:55-14:40)
14:40-16:10 [AS02]
Asian Session 2
(14:40-15:40)
[JS02]
KOGO-KSH Joint Session
(14:40-16:10)
[SS04]
Stem Cell: Biology and Therapeutic Target
(14:40-16:10)
[MS01]
MOU Country Session
(14:40-15:40)
[SS07]
Benign Hematology
(14:40-16:10)
[ES04]
Myeloproliferative Neoplasm
(14:40-16:10)
16:10-16:25 Break Break
16:25-17:55 [JS03]
EHA-KSH Joint Symposium 1 - Basic
(16:25-18:05)
[SS05]
Multiple Myeloma
[ES02]
Rare Hematologic Disorders
[JS05]
EHA-KSH Joint Symposium 2
-Clinical Translational
(16:25-18:05)
[SS08]
Supportive Care
[SS09]
Bone Marrow Failure Syndrome
  • *Session Codes
    PL: Plenary Lecture    SS: Scientific Session    ES: Educational Session    JS: Joint Sympoisum    SY: Satellite Symposium
Date Thursday, April 1, 2021
Room ROOM 1 ROOM 2 ROOM 3
08:00-09:00 Registration
08:50-09:00 Opening  
9:00-10:30 [SS01] Acute Lymphoblastic Leukemia [SS02] B-Cell Lymphoma [ES01] Myelodysplastic Syndrome
Contemporary Treatment of Pediatric Ph+ ALL
Kirk Schultz, Canada
Diffuse Large B-cell Lymphoma: at the crossroad of Genetics and Epigenetics
Laura Pasqualucci, USA
Myelodysplastic Syndrome and Overlap Syndrome
Yoon Hwan Chang, Korea
Current Treatment Approaches to Newly Diagnosed Adult ALL
Daniel Joseph DeAngelo, USA
Immunotherapy for Hodgkin Lymphoma
John Kuruvilla, Canada
MDS with Genetic Predisposition
Meerim Park, Korea
Results of High Risk and Novel Subtypes of Pediatric ALL in Japan
Katsuyoshi Koh, Japan
Optimal Treatment of High-Risk Aggressive B-Cell Lymphoma
Lorenz Trümper, Germany
Diagnosis and Treatment of Chronic Myelomonocytic Leukemia
Jihyun Kwon, Korea
10:30-11:15 Plenary Lecture I - Cutting Edge of Emerging Therapies
Clonal Hematopoiesis and the Origins of Hematologic Malignancies
Benjamin Ebert, USA
11:15-11:30 Break
11:30-12:10 [SY01] Satellite Symposium 1 [SY02] Satellite Symposium 2 [SY01] Satellite Symposium 3
New Treatment Option for FLT3 mutant AML
Alexander Edward Perl, USA
Latest Treatment for Hemophilia A and B in Japan
Keiji Nogami, Japan
Optimal Treatment with IMiDs in Newly Diagnosed Multiple Myeloma
Pieter Sonneveld, The Netherlands
12:10-12:55 E-poster Exhibition
12:55-14:25 [AS01] Asian Session I
-Recent Therapeutic Approaches in CML(12:55-13:55)
[JS01] KAI-KSH Joint Session [SS03] Advances in Technology
From Korean Perspective
Young Rok Do, Korea
Regulating Regulatory T Cells for Enhancement of Cancer Immunotherapy
Sang-Jun Ha, Korea
Incorporating Genetics into Clinic
Elli Papaemmanuil, USA
From Chinese Perspective
Qian Jiang, China
IL-17-Producing Cells in Tumor
Yeon Seok Chung, Korea
Intelligent Image-Activated Cell Sorting: Principles and Application to Hematology
Akihiro Isozaki, Japan
From Japanese Perspective
Shinya Kimura, Japan
Pro-Inflammatory Cytokines in Graft-Versus-Host Disease (GVHD)
Young-Woo Jeon, Korea
HARMONY: A Big Data for Better Outcomes Project in Hematological Malignancies
Jesús María Hernández Rivas, Spain
Harnessing Adaptive Natural Killer Cells for Immunotherapy in Multiple Myeloma
Hyunsoo Cho, Korea
14:25-14:40 Coffee Break
14:40-16:10 [AS02] Asian Session II
-Updates of Hematologic Disease in Asian Population
(14:40-15:40)
[JS02] KOGO-KSH Joint Session [SS04] Stem Cell: Biology and Therapeutic Target
Management of TDT and NTDT Thalassemia in Indonesia
Tubagus Djumhana Atmakusuma, Indonesia
Single Cell RNA Sequencing Reveals Transcriptional Programs Associated with Myeloma Progression
Hae-Ock Lee, Korea
Discovery of New Regulators in Stem Cells and Malignancies
Dongjun Lee, Korea
Hemophilia Treatment in Singapore
Tien Sim Leng, Singapore
Multi-Omics Analysis and Modeling of DNA Methylation in Cancer
Sun kim, Korea
AMD1 Is Essentially Required in Leukemic Stem Cells
Hyog Young Kwon, Korea
Thalassemia Treatment in Malaysia
Jameela Sathar, Malaysia
Clinical Application of Next-Generation Sequencing in Acute Myeloid Leukemia
Jae-Sook Ahn, Korea
BCL-2 as a Stem Cell Target in AML
Daniel A. Pollyea, USA
Challenges in the Introduction of Next-Generation Sequencing for Diagnostics of Hematologic Malignancies
Seung-Tae Lee, Korea
16:10-16:25 Break
16:25-17:55 [JS03] EHA-KSH Joint Symposium 1
- Basic -
(16:25-18:05)
[SS05] Multiple Myeloma [ES02] Rare Hematologic Disorders
Clonal Evolution under IDH Inhibitor Therapy in AML
Lynn Quek, UK
Novel Strategies to Overcome Relapsed/Refractory Multiple Myeloma
Suzanne Trudel, Canada
Molecular Diagnosis of Thalassemia Jee-Soo Lee, Korea
TBD
Kimmo Porkka, Finland
MRD Negativity - The Foremost Important Goal of Myeloma Treatment?
Bruno Paiva, Spain
Current Understanding and Treatment Strategies of Langerhans Cell Histiocytosis Kyung-Nam Koh, Korea
TET Loss-of-Function in Malignant Hematopoiesis
Myunggon Ko, Korea
Light Chain Amyloidosis Ki Hyun Kim, Korea Pathogenesis and Treatment Overview on Secondary Hemophagocytic Lymphohistiocytosis Yu Ri Kim, Korea
Novel Small Molecule Drug Discovery to Override NRAS-mutated AML Taebo Sim, Korea
Date Friday, April 2, 2021
Room ROOM 1 ROOM 2 ROOM 3 ROOM 4
08:00-09:00 Registration
9:00-10:30 [JS04] ASH-KSH Joint Symposium
- ALL -
[SS06] Thrombotic issues in hematology [ES03] Lymphoma
Novel diagnosis and management of B-cell lymphoma 
Epigenetic Control in T-Cell Acute Lymphoblastic Leukemia
Marjorie Brand, Canada
Direct Oral Anticoagulants for the Treatment of VTE in Cancer Patients
Marc Carrier, Canada 
B-Cell Lymphoma's New Genomics
Youngil Koh, Korea
TBD
Renier Brentjens, USA
Updates on the Diagnosis and Management of Immune Mediated TTP
Spero Cataland, USA
Immuno-Oncology for B-Cell Lymphomas
Yoon Seok Choi, Korea
Current Concepts in the Management of Relapsed/Refractory ALL in Korean
Joon Ho Moon, Korea
Post-Transplant Thrombotic Microangiopathy
Vahid Afshar-Kharghan, USA
Novel Combination Immunochemotherapy beyond CD20
Jun Ho Yi, Korea
Pediatric Acute Lymphoblastic Leukemia in Korea
Hyoung Jin Kang, Korea
10:30-11:15 Plenary Lecture II - Clinical Hematology Lecture
Genetic Landscape of Lymphoma and Novel Treatment Approaches
Wyndham Hopkins Wilson, USA
11:15-11:30 Coffee Break
11:30-12:10 [SY04] Satellite Symposium 4 [SY05] Satellite Symposium 5 [SY06] Satellite Symposium 6 [SY07] Satellite Symposium 7
Ravulizumab: Next Generation of C5 Inhibitor for the Standard Care of PNH
Jin Seok Kim, Korea
DLBCL Treatment Strategy in Relapsed and Refractory Setting - Role of Polatuzumab
Laurie Sehn, Canada
Treatment Strategies in Relapsed and Refractory Multiple Myeloma: A Focus on Sequential Treatment for Survival Benefit
Joseph Mikhael, USA
When and How to Treat Front-Line Chronic Lymphocytic Leukemia?
Philip A. Thompson, USA
12:10-12:40 E-poster Exhibition
12:40-13:40 [OP01]
Acute Leukemia
[OP02]
Laboratory Hematology
[OP03]
Lymphoma and MM
[OP04]
Benign Hematology
(Anemia, Thrombocytopenia)
13:40-13:55 Break
13:55-14:40 Presidential Symposium 
The Evolution of Acute Leukemia Diagnostics and Its Place in Treatment
Elizabeth Macintyre, France
14:40-16:10 [MS01] MOU Country Session
-Lymphoid Malignancy-
(14:40-15:40)
[SS07] Benign Hematology  [ES04] Myeloproliferative Neoplasm
Outcome of Autologous Transplant in T-Cell Lymphoma: Experience of NIHBT in Vietnam
Nguyen Vu Bao Anh, Vietnam
Novel Therapies for ITP
Cindy Neunert, USA
The Role of Interferon for the Treatment of MPNs
Seug Yun Yoon, Korea
Subcutaneous Panniculitis-like T-Cell Lymphoma
Udomsak Bunworasate, Thailand
Recent Understandings of Congenital Neutropenia
Hyoung Soo Choi, Korea
Allogeneic Hematopoietic Cell Transplantation for Treatment of Myelofibrosis Patients in JAK Inhibitor Era
Sung-Yong Kim, Korea
Update of Extranodal NK/T-cell Lymphoma: Treatment and Biology
Seok Jin Kim, Korea
Non-Factor Approach including Emicizumab
Keiji Nogami, Japan
To Modify the Disease Course of MPNs
Sung-Eun Lee, Korea
16:10-16:25  Break
16:25-17:55 [JS05] EHA-KSH Joint Symposium 2
-Clinical-Translational-
(16:25-18:05)
[SS08] Supportive Care [SS09] Bone Marrow Failure Syndrome 
Immunotherapy in AML: From alloSCT towards CAR-T Cell Therapy
Charles Craddock, UK
Improving Palliative Care and Outcomes in Low- and Middle-Income Countries
Scott Howard, USA
Challenges in the Diagnosis of Bone Marrow Failure Syndromes: The Role of Genetic Panels?
Ghulam J Mufti, UK
The Emerging Role of MRD in AML
Gert Ossenkoppele, The Netherlands
Renal Supportive Care and Palliative Care in Patients with Hematologic Diseases
Chung Hee Baek, Korea
Clonal Hematopoesis in Bone Marrow Failure
Austin G Kulasekararaj, UK
Resistance Mechanism to Venetoclax and Overcoming in AML
Ji Eun Jang, Korea
Vaccinations before/after Biologic Agents in Patients with Hematologic Malignancies
Wan Beom Park, Korea
Current Guidelines for the Treatment of Acquired Aplastic Anemia in Japan: An Immune Marker-Based Approach
Shinji Nakao, Japan
MRD in AML
Byung Sik Cho, Korea
Date Saturday, April 3, 2021
Room ROOM 1 ROOM 2 ROOM 3
07:30-08:30 Business Meeting
08:30-09:00 Working Party Reports
09:00-10:30 [SS10] Immunotherapy/Transplantation [SS11] Pediatric Disease [SS12] T-Cell Lymphoma /HD
CD8+ TILs Bifurcate Divergent Differentiation Trajectory toward TEMRA in Non-Small Cell Lung Cancer Patients, Deciphering an Immunogenicity of Tumor Antigens
Jae-Ho Cho, Korea
Juvenile Myelomonocytic Leukemia: Learning from Patients in a World Without Walls
Mignon Loh, USA
PD-L1 and NK/T-Cell Lymphoma
Won Seog Kim, Korea
Immunosenescent Characteristics of T Cells in Young Patients Following Haploidentical HSCT from Parental Donors
Won-Woo Lee, Korea
Sirolimus Therapy for Vascular Anomaly
Keon Hee Yoo, Korea
Novel Agents for Peripheral T Cell Lymphomas
Francine Foss, USA
CAR T Cells for AML: Lessons from the Clinic
Saar Gill, USA
Langerhans Cell Histiocytosis 2021: New Insights and Opportunities
Carl Allen, USA
A Translational Research in Angioimmunoblastic T-Cell Lymphoma: From Genome to Bedside
Sakata-Yanagimoto Mamiko, Japan
10:30-11:15 Plenary Lecture III - Genomics in Hematologic Malignancies 
Latest Treatment Developments in Multiple Myeloma
Nikhil Munshi, USA
11:15-11:30 Coffee Break
11:30-12:10 [SY08] Satellite Symposium 8 [SY09] Satellite Symposium 9 [SY10] Satellite Symposium 10
Updated ASH ITP Treatment Guideline and Its Implications for Clinical Practice
Waleed Ghanima, Norway
The Efficacy and Safety of Pegfilgrastim and PEGylated G-CSFs: Real World Experience in DLBCL
Yong Park, Korea
Real-World Outcomes and Factors Impacting Treatment Choice in Relapsed/Refractory Multiple Myeloma
Ji Hyun Lee, Korea
12:10-12:55 Award Ceremony & Closing
ORGANIZED BY
SUPPORTED BY

Sponsored by